Last reviewed · How we verify
AZD9150, Durvalumab
At a glance
| Generic name | AZD9150, Durvalumab |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Procedural pain
- Decreased appetite
- Dyspnoea
- Neutropenia
- Asthenia
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Cough
- Anaemia
- Thrombocytopenia
- Diarrhoea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9150, Durvalumab CI brief — competitive landscape report
- AZD9150, Durvalumab updates RSS · CI watch RSS
- AstraZeneca portfolio CI